ENSC on Nasdaq

Ensysce Biosciences

Logo: ensysce.com3

American biotechnology company that raised $102.6 million in 2026 (SEC Form D). Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

2003Founded1

Compare with Petros Pharmaceuticals, Inc., Adlai Nortye Group Ltd. or PROCYON CORP, or pick any stock.

  • TickerENSC on Nasdaq1
  • Industrybiotechnology industry1
  • HeadquartersLa Jolla, California1
  • Websiteensysce.com
  • Incorporated inDE4
  • Business address7946 Ivanhoe Avenue, Suite 201, La Jolla, Ca 920374
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Ensysce Biosciences image from its website
Image: ensysce.com3

May of 2023. PF614-MPAR was granted Breakthrough Therapy designation by the FDA in January 2024.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-202.1%Operating margin6
-200.8%Net margin6
-2.8%Revenue growth, 20256
-316.6%Return on equity6
-$7.9MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$10.4M

Out of $5.1M in revenue.6 The company lost money this year.

Financial statements

Revenue789106$5.1M in 2025+29% since 2020
0$2.0M$4.0M$6.0M2020: $3.9M$3.9M20202021: $3.5M$3.5M2021−10%2022: $2.5M$2.5M2022−29%2023: $2.2M$2.2M2023−12%2024: $5.2M$5.2M2024+134%2025: $5.1M$5.1M2025−3%
Operating income11789106-$10.2M in 2025+208% since 2019
-$30.0M-$20.0M-$10.0M02019: -$3.3M-$3.3M20192020: -$1.6M-$1.6M2020−52%2021: -$19.9M-$19.9M2021+1132%2022: -$24.2M-$24.2M2022+22%2023: -$10.7M-$10.7M2023−56%2024: -$6.7M-$6.7M2024−37%2025: -$10.2M-$10.2M2025+52%
Net income1189106-$10.2M in 2025+853% since 2019
-$30.0M-$20.0M-$10.0M0$10.0M2019: -$1.1M-$1.1M20192020: $4.3M$4.3M20202021: -$29.1M-$29.1M20212022: -$24.2M-$24.2M2022−17%2023: -$10.6M-$10.6M2023−56%2024: -$8.0M-$8.0M2024−25%2025: -$10.2M-$10.2M2025+27%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Federal grants$5.1M$5.2M
Research and development$10.4M$7.2M
General and administrative$4.9M$4.7M
Total operating expenses$15.3M$11.9M
Loss from operations-$10.2M-$6.7M
Change in fair value of liability classified warrants$10.1K$16.3K
Interest expense, net-$18.8K-$1.3M
Other income and expense, net$73.4K$17.3K
Total other income (expense), net$64.8K-$1.3M
Net loss-$10.2M-$8.0M
Net loss attributable to noncontrolling interests-$487-$74
Deemed dividend related to warrants down round provision$290
Net loss attributable to common stockholders-$10.2M-$8.0M
Net loss per share attributable to common stockholders, basic-$3.98-$11.45
Net loss per share attributable to common stockholders, diluted-$3.98-$11.45
Weighted average common shares outstanding, basic2.6M shares697.7K shares
Weighted average common shares outstanding, diluted2.6M shares697.7K shares

Compare Ensysce Biosciences with another company

Leadership

Who has led Ensysce Biosciences, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Daniel B. Silvers2017–2018
  2. Lynn Kirkpatrick2021–2022

Chair

  1. A. Lorne Weil2017–2018

President

  1. James William Morrison2026–now

Chief financial officer

  1. George Peng2017–2018

Chief operating officer

  1. Jeffrey Millard2021
20052010201520202025
Board members and other officers (18)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerDavid Lynn Humphrey named Oct 6, 2021 to Aug 20, 202635

Former names

  • Leisure Acquisition Corp.Oct 3, 2017 to Jun 30, 20214

Timeline

  1. Jul 2, 2021New chief executive Lynn Kirkpatrick becomes CEO14
  2. Dec 1, 2017New chief executive Daniel B. Silvers becomes CEO15
  3. 2003Founded Founded1

Filings

319 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 82 major events, 27 insider forms, 21 large holders, 8 private raises, 161 other. The latest 20:

  1. Sep 29, 20268-K EDGAR
  2. Aug 25, 20268-K EDGAR
  3. Aug 24, 20268-K EDGAR
  4. Aug 20, 2026D EDGAR
  5. Aug 18, 2026SCHEDULE 13D/A EDGAR
  6. Aug 18, 20264 EDGAR
  7. Aug 13, 202610-Q EDGAR
  8. Aug 13, 20268-K EDGAR
  9. Aug 10, 20263 EDGAR
  10. Aug 6, 20268-K/A EDGAR
  11. Aug 6, 20268-K EDGAR
  12. Jul 15, 20268-K EDGAR
  13. Jun 26, 2026EFFECT EDGAR
  14. Jun 4, 2026S-3 EDGAR
  15. May 22, 20268-K EDGAR
  16. May 15, 202610-Q EDGAR
  17. May 15, 20268-K EDGAR
  18. Apr 30, 2026S-8 EDGAR
  19. Apr 15, 2026EFFECT EDGAR
  20. Apr 14, 2026CORRESP EDGAR

The 319 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 8 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 7, 2026GOWER BOB GDirectorBuy400,000$0.50$200.0KForm 4
Apr 23, 2026GOWER BOB GDirectorBuy508,614$0.48$244.1KForm 4
Mar 2, 2023GOWER BOB GDirectorBuy90,287$0.49$44.2KForm 4
Mar 1, 2023GOWER BOB GDirectorBuy270,000$0.48$129.6KForm 4
Feb 28, 2023GOWER BOB GDirectorBuy109,300$0.49$53.6KForm 4
Dec 9, 2022GOWER BOB GDirectorBuy357,143$1.40$500.0KForm 4
May 26, 2022Kirkpatrick LynnChief Executive OfficerBuy27,000$0.53$14.3KForm 4
May 25, 2022Kirkpatrick LynnChief Executive OfficerBuy70,000$0.49$34.3KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Aug 5, 2026Raised $77.2 million in a private offering of equity Form D: 44 investors so far Form D
  2. Apr 23, 2025Raised $2.2 million in a private offering of securities Form D: 8 investors so far Form D
  3. Mar 31, 2025Raised $1.1 million in a private offering of securities Form D: 8 investors so far Form D
  4. Aug 29, 2024Raised $5.1 million in a private offering of securities Form D: 4 investors so far Form D
  5. Feb 14, 2024Raised $4.7 million in a private offering of securities Form D: 4 investors so far Form D
  6. Feb 2, 2023Raised $2.8 million in a private offering of securities Form D: 8 investors so far Form D
  7. Jun 30, 2022Raised $4.2 million in a private offering of debt Form D: $8.5 million offered in all Form D
  8. Sep 24, 2021Raised $5.3 million in a private offering of debt Form D: $15.9 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Jane Street Group, LLC208,833$60.6K0.0%+195,263
Adage Capital Partners Gp, L.l.c.149,711$43.4K0.0%No change
Perceptive Advisors LLC86,666$25.1K0.0%No change
Citadel Advisors LLC86,193$25.0K0.0%+28,830
XTX Topco Ltd77,005$22.3K0.0%+52,642
Geode Capital Management, LLC62,188$18.0K0.0%−11,692
Susquehanna International Group, Llp34,280$9.9K0.0%New
Tru Independence Asset Management 2, LLC13,000$3.8K0.0%No change
Two Sigma Securities, LLC12,953$3.8K0.0%New
Vanguard Capital Management LLC12,854$3.7K0.0%No change
Tower Research Capital LLC (TRC)6,094$1.8K0.0%No change
Barclays PLC1,440$4180.0%New
SBI Securities Co., Ltd.641$1860.0%+155
Virtu Financial LLC95,391$280.0%+82,078
BlackRock, Inc.65$190.0%No change
Hrt Financial LP54,429$150.0%New
Clear Street Group Inc.1$00.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45